ARTICLE | Company News
Numab, Kaken partner to discover multi-specific antibody for inflammatory disease
June 16, 2017 8:30 PM UTC
Numab Therapeutics AG (Pfaeffikon, Switzerland) and Kaken Pharmaceutical Co. Ltd. (Tokyo:4521) partnered to identify a multi-specific antibody candidate for an
undisclosed inflammatory indication using Numab’s discovery platform...